CNTA

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company developing innovative medicines across a broad range of serious diseases. Headquartered in London, United Kingdom, with offices in Waltham, Massachusetts, Centessa operates a unique asset-centric model with multiple R&D programs spanning oncology, hematology, immunology, and rare diseases. The company's pipeline includes programs acquired from academic institutions and biotechnology companies, each with its own dedicated development team. Centessa's lead programs include therapies for acute myeloid leukemia, autoimmune diseases, and solid tumors. The company aims to advance multiple product candidates simultaneously while maintaining operational efficiency through its centralized platform that provides shared resources and expertise across programs.